Advertisement
Canada markets open in 6 hours 29 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7329
    +0.0006 (+0.09%)
     

  • CRUDE OIL

    83.96
    +0.39 (+0.47%)
     

  • Bitcoin CAD

    87,832.83
    +145.69 (+0.17%)
     

  • CMC Crypto 200

    1,388.41
    -8.13 (-0.58%)
     

  • GOLD FUTURES

    2,353.60
    +11.10 (+0.47%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,777.75
    +210.25 (+1.20%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    0.00 (0.00%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

What's Next for Trevena? Pipeline and Analysts Review

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Trevena, Inc. (TRVN), a biopharmaceutical company focused on providing therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain.

The company shares recently fell from $3.47 per share to today's price of $.91 per share on the heels of an adverse FDA decision.

More about the TRVN pipeline, FDA status, analysts review, and more in this full report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/trevena/

ADVERTISEMENT

On October 11th, the company announced the outcome of the meeting of the FDA Anesthetic and Analgesic Drug Products Advisory Committee to review and discuss oliceridine. The Advisory Committee voted eight against, and 7 in favor of, the approval of oliceridine for the management of moderate to severe acute pain in adult patients for whom an intravenous (IV) opioid is warranted.

TRVN pipeline, analyst target and corporate review in this full report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/trevena/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source